Nonalcoholic steatohepatitis (NASH) is considered the progressive form of nonalcoholic fatty
liver disease (NAFLD) and is characterized by liver steatosis, inflammation, hepatocellular …

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and
a major cause of liver cirrhosis and hepatocellular carcinoma. NAFLD is intimately linked …

Hepatocytes have important roles in liver iron homeostasis, abnormalities in which are
tightly associated with liver steatosis and fibrosis. Here, we show that non-alcoholic fatty liver …

Non-alcoholic fatty liver disease (NAFLD) is often the hepatic expression of metabolic
syndrome and its comorbidities that comprise, among others, obesity and insulin-resistance …

Non-alcoholic fatty liver disease (NAFLD) is common, affecting approximately 25% of the
general population. The evidence base for the investigation and management of NAFLD is …

Liver fibrosis is characterised by excessive deposition of extracellular matrix that interrupts
normal liver functionality. It is a pathological stage in several untreated chronic liver …

The gut microbiota acts as a symbiotic microecosystem that plays an indispensable role in
the regulation of a number of metabolic processes in the host by secreting secondary …

Non‐alcoholic fatty liver disease (NAFLD), recently re‐defined and re‐classified as
metabolic dysfunction‐associated fatty liver disease (MAFLD), has become increasingly …

Melanoma, the most aggressive skin cancer, is mainly treated with BRAF inhibitors or
immunotheareapy. However, most patients who initially responded to BRAF inhibitors or …

Most currently recommended therapies for metabolic dysfunction-associated fatty liver
disease (MAFLD) involve diet control and exercise therapy. We searched PubMed and …